Role of Fingolimod in Attenuation of LCL to Reduced Apoptosis in Myocardial Ischemia Reperfusion Injury
Naseer Ahmed, Humaira Achakzai, M. Naveed Anwar, Shahida Perveen, Malik Irfan M., Sami S., M. Z. Yusuf, Azam J., Alessio R.
3080
ABSTRACT
Background: FTY720 (Fingolimod) is a drug having
immune-regulatory properties. It is a structurally analogous to
Sphingosine-1-phosphate. S1P is a biologically active lipid mediator in various
inflammatory pathways.
Aim: To investigate the effects of FTY720 on myocardial
ischemia reperfusion (IR) injury in cardiac surgery.
Study design: Experimental study
Place and duration of study: Aga Khan University, Karachi and Khyber
Medical University, Peshawar Pakistan from 1st January 2017 to 31st
December 2020 with collaboration of University of Verona, Italy.
Methodology: Twenty Sprague-Dawley rats were
segregated into two groups; treatment and control. In treatment group received
FTY720 at 1 mg/kg, intravenously 15 minutes prior to the experiment. Both
groups were exposed to myocardial ischemia (30 m) reperfusion (2 h). Blood gas
analysis, lymphocyte count, myeloperoxidase assay and TUNEL assay were
performed and analyzed to observe the effect of FTY720 on neutrophil
infiltration and apoptosis.
Results: FTY720 treated group had improvement in blood
gas levels in contrast to the control, treatment group also experienced
decrease in neutrophil infiltration, lymphocyte count and myeloperoxidase
enzyme expression.
Conclusions: FTY720 pre-treatment reduce lymphocyte
count that leads to reduce the level of apoptosis and salvage the myocardial
damage incurred by ischemia reperfusion.
Keywords: Fingolimod, Cardiopulmonary bypass,
Lymphocyte, Neutrophil, Myeloperoxidase